Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Cipla
Merck
Accenture
US Army

Generated: May 21, 2019

DrugPatentWatch Database Preview

Genus Lifesciences Company Profile

« Back to Dashboard

What is the competitive landscape for GENUS LIFESCIENCES, and what generic alternatives to GENUS LIFESCIENCES drugs are available?

GENUS LIFESCIENCES has nine approved drugs.

There are eight US patents protecting GENUS LIFESCIENCES drugs.

There are forty-four patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and twenty-two supplementary protection certificates in eleven countries.

Summary for Genus Lifesciences
International Patents:44
US Patents:8
Tradenames:8
Ingredients:8
NDAs:9

Drugs and US Patents for Genus Lifesciences

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-002 Jun 6, 2003 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Genus Lifesciences GOPRELTO cocaine hydrochloride SOLUTION;NASAL 209963-001 Dec 14, 2017 RX Yes Yes 10,016,407 ➤ Try a Free Trial ➤ Try a Free Trial
Genus Lifesciences POTASSIUM CHLORIDE potassium chloride SOLUTION;ORAL 206814-002 Dec 22, 2014 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 9,987,231 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 81 mg/40 mg ➤ Subscribe 2016-10-14

Supplementary Protection Certificates for Genus Lifesciences Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 08C0026 France ➤ Try a Free Trial PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
1411900 C01411900/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
1411900 122012000052 Germany ➤ Try a Free Trial PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0253310 SPC/GB95/010 United Kingdom ➤ Try a Free Trial PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1441735 SPC/GB08/020 United Kingdom ➤ Try a Free Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Deloitte
Mallinckrodt
AstraZeneca
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.